Trevena (TRVN) Stock Price, News & Analysis

Company Overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Key Stats

• Today's Range: $1.67 to $1.67
• 50-Day Range: $1.49 to $1.86
• 52-Week Range: $1.13 to $17.50
• Volume: 1,258 shs
• Average Volume: 3,147 shs
• Market Capitalization: $1.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Trevena Stock Analysis - MarketRank™

Trevena scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Trevena has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Trevena has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Trevena are expected to grow in the coming year, from ($23.04) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevena is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevena is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TRVN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevena does not currently pay a dividend.

Dividend Growth

Trevena does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TRVN.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Trevena this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Trevena to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trevena insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Trevena is held by insiders.

Percentage Held by Institutions

Only 13.56% of the stock of Trevena is held by institutions.

TRVN Stock Analysis - Frequently Asked Questions

How have TRVN shares performed this year?

Trevena's stock was trading at $1.50 at the start of the year. Since then, TRVN stock has increased by 11.3% and is now trading at $1.67.
View the best growth stocks for 2025 here.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company earned $0.33 million during the quarter.

When did Trevena's stock split?

Shares of Trevena reverse split on the morning of Tuesday, August 13th 2024. The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Trevena's major shareholders?

Top institutional shareholders of Trevena include Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Sorrento Therapeutics (SRNE), NIO (NIO), TherapeuticsMD (TXMD), Cara Therapeutics (CARA) and SCYNEXIS (SCYX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVN
• CUSIP: N/A
• CIK: 1429560
• Web: www.trevena.com
• Phone: (610) 354-8840
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +199.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($47.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,290,000.00
• Net Margins: N/A
• Pretax Margin: -6,222.30%
• Return on Equity: N/A
• Return on Assets: -119.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.42
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: $3.12 million
• Price / Sales: 0.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.07) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 860,000
• Free Float: 841,000
• Market Cap: $1.44 million
• Optionable: Optionable
• Beta: 1.08